1. Others
  2. Androgen Receptor
  3. Dimethylcurcumin

Dimethylcurcumin (Synonyms: ASC-J9; GO-Y025)

Cat. No.: HY-15194 Purity: 98.06%
Handling Instructions

Dimethylcurcumin (ASC-J9) is an androgen receptor degradation enhancer that effectively suppresses castration resistant prostate cancer cell proliferation and invasion.

For research use only. We do not sell to patients.

Dimethylcurcumin Chemical Structure

Dimethylcurcumin Chemical Structure

CAS No. : 52328-98-0

Size Price Stock Quantity
Free Sample (0.5-1 mg)   Apply now  
10 mM * 1 mL in DMSO USD 158 In-stock
Estimated Time of Arrival: December 31
5 mg USD 144 In-stock
Estimated Time of Arrival: December 31
10 mg USD 240 In-stock
Estimated Time of Arrival: December 31
50 mg USD 792 In-stock
Estimated Time of Arrival: December 31
100 mg   Get quote  
200 mg   Get quote  

* Please select Quantity before adding items.

Customer Review

Top Publications Citing Use of Products

    Dimethylcurcumin purchased from MCE. Usage Cited in: Tumour Biol. 2015 Nov;36(11):8727-33.

    Application of ASC-J9 (an AR degradation enhancer) to 22Rv1 cell line also represses androgen-induced Gabarapl1 upregulation.

    Dimethylcurcumin purchased from MCE. Usage Cited in: Biochem Biophys Res Commun. 2017 Apr 15;485(4):746-752.

    ASC-J9 inhibits M1 polarization of Raw264.7 cells. (A) Western blotting and analysis of iNOS in Raw264.7 cells stimulated with LPS in each group. (B) Western blotting and analysis of SOCS1 and p-STAT5 expression in Raw264.7 cells stimulated with LPS in each group.

    Dimethylcurcumin purchased from MCE. Usage Cited in: Oncotarget. 2016 Jun 14;7(24):36814-36828.

    Protein levels of AR and NANOG expression is measured in NanogPos and NanogNeg cells from T1224+1 and Huh7+7 after treatment with DHT and with or without ASC-J9 for 24h. The addition of ASC-J9 attenuates the DHT effect and reduces the expression of AR and Nanog in both groups.

    Dimethylcurcumin purchased from MCE. Usage Cited in: Biochem Pharmacol. 2017 Sep 15;140:73-88.

    Androgen receptors levels in RAW264.7 cells treated with ASC-J9. Cells are treated with or without ASC-J9 for 30 min or 12 h and cells lysate is examined by western blotting using antibodies for the Androgen Receptor and GAPDH.

    Dimethylcurcumin purchased from MCE. Usage Cited in: J Ovarian Res. 2018 May 2;11(1):36.

    Oct4 and Sox2 expression in the GFP (+) cells clearly increased under DHT treatment compared with ASC-J9 treatment based on western blot analysis, which is also consistent with the Nanog expression trend.

    Dimethylcurcumin purchased from MCE. Usage Cited in: Biochem Biophys Res Commun. 2018 Nov 17;506(1):130-136.

    The protein expression level of AR in EAM mice with/without ASC-J9 treatment is analysed.

    Dimethylcurcumin purchased from MCE. Usage Cited in: Biochem Biophys Res Commun. 2018 Nov 17;506(1):130-136.

    Treatment with ASC-J9 in the presence of TGF-b decreases the mRNA expression of collagen I and a-SMA.
    • Biological Activity

    • Protocol

    • Technical Information

    • Purity & Documentation

    • References

    Description

    Dimethylcurcumin (ASC-J9) is an androgen receptor degradation enhancer that effectively suppresses castration resistant prostate cancer cell proliferation and invasion.

    In Vitro

    Dimethylcurcumin (ASC-J9) is able to degrade fAR and AR3 in a dose-dependent manner in various human PCa cells. Dimethylcurcumin (ASC-J9) can also effectively suppress AR-targeted genes in CWR22Rv1-fARKD cells. Dimethylcurcumin (ASC-J9) (5 or 10 µM) significantly suppresses the DHT-induced cell growth in all three PCa cell lines. Dimethylcurcumin (ASC-J9) suppresses AR-targeted genes and cell growth by degradation of fAR and ectopic AR3 in C81 and C4-2 cells[1]. Dimethylcurcumin (ASC-J9) selectively promotes AR degradation by disrupting the interaction between AR and AR coregulators. ASC-J9 reduces the AR aggregated AR-112Q in cells. Dimethylcurcumin (ASC-J9) suppresses the aggregation of AR-112Q in SBMA PC12/AR-112Q cells[2].

    In Vivo

    Dimethylcurcumin (ASC-J9) (75 mg/kg, i.p.) degrades both fAR and AR3 in the xenografted tumors in vivo, and SC-J9-treated tumors has significantly decreased Ki67-positive cells[1]. Dimethylcurcumin (ASC-J9) (50 mg/kg every 48 h, i.p.) substantially ameliorates the SBMA symptoms in AR-97Q mice, and ameliorates neuromuscular pathological findings. The Dimethylcurcumin (ASC-J9)-treated SBMA mice have relatively normal serum testosterone concentrations[2]. ASC-J9-treated mice show significantly smaller prostate tumor sizes when compared with those receiving classic ADT/castration with little serum androgen[3].

    Clinical Trial
    Storage
    Powder -20°C 3 years
      4°C 2 years
    In solvent -80°C 6 months
      -20°C 1 month
    Solvent & Solubility
    In Vitro: 

    DMSO : ≥ 50 mg/mL (126.13 mM)

    H2O : < 0.1 mg/mL (insoluble)

    *"≥" means soluble, but saturation unknown.

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 2.5225 mL 12.6126 mL 25.2251 mL
    5 mM 0.5045 mL 2.5225 mL 5.0450 mL
    10 mM 0.2523 mL 1.2613 mL 2.5225 mL
    *Please refer to the solubility information to select the appropriate solvent.
    In Vivo:
    • 1.

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% saline

      Solubility: ≥ 2.17 mg/mL (5.47 mM); Clear solution

    *All of the co-solvents are provided by MCE.
    References
    Cell Assay
    [2]

    For the cell survival assay, the PC12/AR-112Q and PC12/AR-10Q cells are cultured as described previously and incubated cells in the presence of 10 μg/mL doxycycline for 24 h. Then the cells are treated with vehicle, 5 μM Dimethylcurcumin (ASC-J9) or 10 μM Dimethylcurcumin (ASC-J9), along with 1 nM DHT, and determined cell viability using Trypan blue staining at specific time intervals.

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Administration
    [1]

    CWR22Rv1 cells (1×106 cells per site) are injected into both anterior prostates of castrated nude mouse after 2 weeks of implantation. The mice are randomLy divided into two groups (four mice/eight tumors each group) and either receives 75 mg/kg Dimethylcurcumin (ASC-J9) intraperitoneal injection or vehicle control every other day. After 4 weeks of treatment, all mice are killed to examine the tumor growth. Body weights and mice activity are measured weekly.

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    References
    Molecular Weight

    396.43

    Formula

    C₂₃H₂₄O₆

    CAS No.

    52328-98-0

    SMILES

    O=C(/C=C(O)/C=C/C1=CC=C(OC)C(OC)=C1)/C=C/C2=CC=C(OC)C(OC)=C2

    Shipping

    Room temperature in continental US; may vary elsewhere

    Purity: 98.06%

    • Molarity Calculator

    • Dilution Calculator

    The molarity calculator equation

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass   Concentration   Volume   Molecular Weight *
    = × ×

    The dilution calculator equation

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
    × = ×
    C1   V1   C2   V2

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product name

     

    Salutation

    Applicant name *

     

    Email address *

    Phone number *

     

    Organization name *

    Country or Region *

     

    Requested quantity *

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Dimethylcurcumin
    Cat. No.:
    HY-15194
    Quantity:

    Dimethylcurcumin

    Cat. No.: HY-15194